Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PAVM
stocks logo

PAVM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
25.00K
+150%
-0.200
+233.33%
74.00K
+825%
-0.200
+185.71%
98.00K
+1533.33%
-0.190
+280%
Estimates Revision
The market is revising No Change the revenue expectations for PAVmed Inc. (PAVM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.46%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-23.46%
In Past 3 Month
Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.341
sliders
Low
20.00
Averages
20.00
High
20.00
Current: 0.341
sliders
Low
20.00
Averages
20.00
High
20.00
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$19 → $20
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$19 → $20
2025-04-21
Maintains
Strong Buy
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$21 → $19
2024-12-09
Reason
Ascendiant Capital
Edward Woo
Price Target
$21 → $19
2024-12-09
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for PAVmed Inc (PAVM.O) is -0.41, compared to its 5-year average forward P/E of -2.79. For a more detailed relative valuation and DCF analysis to assess PAVmed Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.79
Current PE
-0.41
Overvalued PE
2.08
Undervalued PE
-7.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.37
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.12
Undervalued EV/EBITDA
-6.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
63.74
Current PS
0.00
Overvalued PS
167.50
Undervalued PS
-40.02
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

PAVM News & Events

Events Timeline

(ET)
2025-08-26
08:05:37
PAVmed Secures Licensing Agreement for Esophageal Imaging Technology from Duke Technology
select
2025-08-14 (ET)
2025-08-14
08:04:55
PAVmed reports Q2 non-GAAP EPS (5c) vs. (84c) last year
select
2025-06-03 (ET)
2025-06-03
08:35:30
PAVmed subsidiary Veris Health partners with Ohio State University cancer center
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-01NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet

  • BioAtla Inc. Gains: BioAtla's shares surged 13.94% in after-hours trading, attributed to investor reactions to recent financing agreements, despite no new company-specific news.

  • Metagenomi Inc. and PAVmed Inc. Movements: Metagenomi's stock rose 5.71% with no new updates, while PAVmed advanced 5.72% after reporting a significant net loss and a sharp decline in revenue.

  • Precision BioSciences' Positive Outlook: Precision BioSciences gained 2.94% after announcing it will present Phase 1 trial data at an upcoming conference, boosting investor optimism.

  • Entero Therapeutics Rebranding: Entero Therapeutics' shares increased 3.68% following its announcement of a rebranding to GridAI Technologies Corp., effective December 1, 2025, along with a new ticker symbol.

[object Object]
Preview
2.0
11-20Newsfilter
Lucid Diagnostics Recognized as a Top-Ranking Honoree in GenomeWeb's 2025 Best Places to Work

  • Recognition of Lucid Diagnostics: Lucid Diagnostics Inc. has been awarded the title of the best workplace in its size category by GenomeWeb's 2025 Best Places to Work program, highlighting its positive workplace culture and commitment to employee development.

  • Company Focus: Lucid Diagnostics specializes in cancer prevention through its innovative EsoGuard® Esophageal DNA Test, aimed at early detection of esophageal precancer in patients with gastroesophageal reflux disease (GERD).

  • Leadership Statement: Shaun O'Neil, President and COO of Lucid, expressed pride in the recognition, emphasizing the company's dedication to a culture of service and excellence for both patients and employees.

  • About GenomeWeb: GenomeWeb is a leading news organization that covers the molecular biology research and diagnostics sectors, providing insights and analysis to professionals in the life sciences field.

[object Object]
Preview
1.0
11-13Newsfilter
Lucid Diagnostics to Join Canaccord Genuity's MedTech, Diagnostics, and Digital Health & Services Forum

  • Company Participation: Lucid Diagnostics Inc. will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York City, with CFO Dennis McGrath available for one-on-one investor meetings.

  • Focus on Cancer Prevention: Lucid Diagnostics specializes in cancer prevention, particularly for patients with gastroesophageal reflux disease (GERD), offering the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device for early detection of esophageal precancer.

  • Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties, such as stock price volatility, regulatory challenges, and market acceptance of Lucid's products.

  • Monitoring COVID-19 Impact: Lucid continues to assess the impact of the COVID-19 pandemic on its business operations, acknowledging that new risks may arise that are difficult to predict.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is PAVmed Inc (PAVM) stock price today?

The current price of PAVM is 0.341 USD — it has increased 6.91 % in the last trading day.

arrow icon

What is PAVmed Inc (PAVM)'s business?

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

arrow icon

What is the price predicton of PAVM Stock?

Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is PAVmed Inc (PAVM)'s revenue for the last quarter?

PAVmed Inc revenue for the last quarter amounts to 5.00K USD, decreased -99.50 % YoY.

arrow icon

What is PAVmed Inc (PAVM)'s earnings per share (EPS) for the last quarter?

PAVmed Inc. EPS for the last quarter amounts to -0.29 USD, decreased -120.14 % YoY.

arrow icon

What changes have occurred in the market's expectations for PAVmed Inc (PAVM)'s fundamentals?

The market is revising No Change the revenue expectations for PAVmed Inc. (PAVM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.46%.
arrow icon

How many employees does PAVmed Inc (PAVM). have?

PAVmed Inc (PAVM) has 39 emplpoyees as of December 05 2025.

arrow icon

What is PAVmed Inc (PAVM) market cap?

Today PAVM has the market capitalization of 10.12M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free